Events

The next CTN Quarterly Steering Committee Meeting is scheduled for Tuesday, September 15, 2026, from 1-3:30pm ET. The agenda includes: Join the meeting here

CME accreditation for providers pending; a certificate of attendance will be available for all attendees (in-person or virtual) Register here (for in-person and virtual attendance) | View program In a recent survey of Washington State healthcare providers about cannabis negative effects, 70% of respondents reported seeing cases of severe abdominal pain, nausea, retching, and relentless vomiting among people reporting heavy cannabis use. This cluster of symptoms is now recognized as Cannabinoid Hyperemesis Syndrome (CHS). As CHS becomes more visible in clinical settings, providers are left navigating care without clear understanding or guidance. At the same time, while 1 in 10 Washingtonians who consumed cannabis in the last year report vomiting and nausea due to their cannabis use2, many people remain skeptical that the condition exists at all, creating challenges for treatment, prevention and health education. To better understand these dynamics, we are making CHS the focus of this year’s ADAI Symposium. Join the University of Washington's Addictions, Drug & Alcohol Institute (home of the CTN Pacific NW Node) on September 18, 2026, to learn more about:   CHS prevalence among adolescents and adults in U.S. emergency departments CHS in Washington State CHS as a contested disease and implications for health communication CHS presentation, treatment, and management across settings Policy recommendations to prevent CHS increase Improving care for individuals with CHS

Join the Northeast Node for the next installment of their Science Series: Using AI and Passive Data to Improve Digital Assessment and Treatment of Substance Use and Mental Health Disorders. Presented by Nicholas C. Jacobson, PhD. Dr. Jacobson, PhD, is an Associate Professor of Biomedical Data Science and Psychiatry at Dartmouth's Geisel School of Medicine, where he directs the AI and Mental Health: Innovation in Technology Guided Healthcare (AIM HIGH) Laboratory. He has published over 130 peer-reviewed papers (H-index: 44), with a large portion focused on using passively collected smartphone and wearable sensor data to detect psychiatric disorders, measure symptom severity, and predict real-time changes in mental health. His work spans data from over 10,000 participants across 100+ countries. In this talk, he will cover how these digital phenotyping methods have been applied within the CTN through the D-TECT study (CTN-0084-A2), his lab's personalized digital therapeutics for co-occurring anxiety, depression, and substance use disorders, and the 6.5-year development of Therabot, a generative AI psychotherapy chatbot. Therabot was tested in the first randomized controlled trial of generative AI psychotherapy, published in the New England Journal of Medicine AI, where 210 participants showed large symptom reductions (d=0.63 to 0.90) and averaged over 6 hours of engagement across 24 days. He will close with implications for substance use treatment research.